Evidence map›Paper›PMID 41579235›Full record

Trial reportSports medicine (Auckland, N.Z.)2026

Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.

Simon Birk Kjær Jensen, Matteo Fiorenza, Christian Rimer Juhl, Rasmus Michael Sandsdal, Emma Jensen, Søren Sonnenborg Seier, Charlotte Janus, Julie Rehné Jørgensen, Martin Bæk Blond, Jens Juul Holst and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Sports medicine (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04122716. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04122716 phase4unknown status

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

Ran2016Enrolled215Registered outcomes28Posted comparisons0ConditionsObesityArmsExercise, liraglutide
PMID 23186644PMID 26132939PMID 26284720PMID 28049736PMID 30052921PMID 27295427PMID 27633186PMID 25287751PMID 23812094PMID 11234459PMID 22436841PMID 22013105other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Simon Birk Kjær JensenDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark. simon.jensen@sund.ku.dk.ORCID http://orcid.org/0000-0002-1437-2150
Matteo FiorenzaDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Christian Rimer JuhlDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Rasmus Michael SandsdalDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Emma JensenDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Søren Sonnenborg SeierDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Charlotte JanusDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Julie Rehné JørgensenDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Martin Bæk BlondClinical and Translational Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
Jens Juul HolstDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Bente Merete StallknechtDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Sten MadsbadDepartment of Endocrinology, Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark.
Thomas BandholmPhysical Medicine and Rehabilitation Research-Copenhagen, Department of Physical and Occupational Therapy, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
Signe Sørensen TorekovDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark. torekov@sund.ku.dk.

Funding

Novo Nordisk Fonden NNF15CC0018486Novo Nordisk Fonden NNF16OC0019968
6 · The paper itself

Abstract

backgroundObesity is associated with impaired physical fitness, including physical functional performance and cardiorespiratory fitness, which affect health-related quality of life and mortality.

objectiveWe aimed to investigate the efficacy of a moderate-to-vigorous intensity exercise program and glucagon-like peptide-1 receptor agonist treatment alone or in combination during weight maintenance for physical fitness.

methodsThis is secondary analysis of a randomized controlled trial involving 193 adults with obesity (age 18-65 years, body mass index 32-43 kg/m

resultsParticipants randomized to exercise performed a median 2.65 session/week (116 min/week at 79% of maximum heart rate) with no significant difference between those who received placebo or liraglutide. Compared with liraglutide alone, the combined treatment decreased time to complete a stair climb test by 1.2 s [95% confidence interval 0.6-1.9] (corresponding to 8.6%) and improved peak oxygen consumption by 3.0 mL/min/kg fat-free mass [95% confidence interval 0.5-5.5]. Exercise alone led to similar benefits, whereas liraglutide alone did not improve physical fitness. Compared with placebo (- 7.8%), relative muscle strength (strength normalized to body weight) was higher with exercise (- 0.4%), liraglutide (+ 1.0%), and the combined treatment (+ 3.3%) because of lower weight and preserved absolute strength.

conclusionsStructured exercise combined with glucagon-like peptide-1-based obesity pharmacotherapy led to clinically meaningful improvements in physical functional performance and cardiorespiratory fitness, in contrast to pharmacotherapy alone. CLINICAL

trial registrationEudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.

Indexed as

Exercise TherapyGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutideObesityPhysical FitnessWeight LossAdolescentAdultAgedCaloric RestrictionCardiorespiratory FitnessCombined Modality TherapyDiet, ReducingFemaleHumansGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutide

Identifiers

PMID41579235
PMCPMC13388483

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.